1. Home
  2. CAPR vs KW Comparison

CAPR vs KW Comparison

Compare CAPR & KW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$30.24

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Kennedy-Wilson Holdings Inc.

KW

Kennedy-Wilson Holdings Inc.

HOLD

Current Price

$11.00

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
KW
Founded
2005
1977
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2011
2007

Fundamental Metrics

Financial Performance
Metric
CAPR
KW
Price
$30.24
$11.00
Analyst Decision
Strong Buy
Sell
Analyst Count
8
1
Target Price
$44.63
$11.00
AVG Volume (30 Days)
968.6K
708.1K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
4.41%
EPS Growth
N/A
50.00
EPS
N/A
0.10
Revenue
N/A
$62,633,000.00
Revenue This Year
N/A
$81.79
Revenue Next Year
$3.31
N/A
P/E Ratio
N/A
$110.10
Revenue Growth
N/A
23.94
52 Week Low
$4.30
$5.98
52 Week High
$40.37
$11.09

Technical Indicators

Market Signals
Indicator
CAPR
KW
Relative Strength Index (RSI) 42.17 64.28
Support Level $26.06 $10.82
Resistance Level $30.06 N/A
Average True Range (ATR) 2.12 0.03
MACD -0.53 0.01
Stochastic Oscillator 19.86 58.14

Price Performance

Historical Comparison
CAPR
KW

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About KW Kennedy-Wilson Holdings Inc.

Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.

Share on Social Networks: